Mood disorders like depression and bipolar disorder involve persistent changes in mood, thinking, and behavior that significantly impair daily functioning. They go well beyond ordinary sadness or moodiness. These conditions arise from complex interactions between brain chemistry, genetics, and life experiences, making them central topics in understanding brain-behavior relationships.
Major Depressive Disorder vs Bipolar Disorder
Symptoms and Diagnostic Criteria
Major Depressive Disorder (MDD) is defined by persistent sadness, hopelessness, and loss of interest in activities, along with changes in sleep, appetite, and energy that impair daily functioning for at least two weeks. Specific symptoms include:
- Depressed mood most of the day, nearly every day
- Anhedonia (inability to feel pleasure) in activities that used to be enjoyable
- Insomnia or hypersomnia (sleeping too little or too much)
- Significant weight loss or gain, or changes in appetite
- Psychomotor agitation (restlessness) or retardation (slowed movements)
- Fatigue or loss of energy
- Feelings of worthlessness or excessive guilt
- Difficulty concentrating or making decisions
- Recurrent thoughts of death or suicide
The DSM-5 requires at least five of these symptoms during the same two-week period, and at least one must be either depressed mood or anhedonia.
Bipolar Disorder is characterized by alternating episodes of mania (or hypomania) and depression, with periods of normal mood in between. Manic episode symptoms include:
- Inflated self-esteem or grandiosity
- Decreased need for sleep (e.g., feeling rested after only 3 hours)
- Increased talkativeness or pressure to keep talking
- Flight of ideas or racing thoughts
- Distractibility
- Increased goal-directed activity or psychomotor agitation
- Excessive involvement in risky activities (unrestrained spending, sexual indiscretions)
Hypomanic episodes have similar symptoms but are less severe and do not cause significant functional impairment.
DSM-5 diagnostic distinctions:
- Bipolar I: Requires at least one full manic episode, which may be preceded or followed by hypomanic or depressive episodes
- Bipolar II: Requires at least one hypomanic episode and one major depressive episode, but no full manic episodes
Classification and Subtypes
Beyond bipolar I and II, other related conditions include:
- Cyclothymic disorder: Chronic mood fluctuations that don't meet full criteria for bipolar disorder or major depression
- Rapid cycling bipolar disorder: Four or more mood episodes (manic, hypomanic, or depressive) within a 12-month period
MDD also has recognized subtypes:
- Melancholic depression: Severe symptoms including psychomotor retardation, early morning awakening, and a near-total loss of pleasure. Mood does not improve in response to positive events. This subtype often has a stronger biological component and may respond better to antidepressant medication.
- Atypical depression: Features mood reactivity (mood temporarily improves with positive events), increased appetite or weight gain, hypersomnia, leaden paralysis (heavy feelings in arms or legs), and heightened sensitivity to interpersonal rejection. This subtype has higher rates of comorbid anxiety disorders.
- Seasonal affective disorder (SAD): Depression that follows a seasonal pattern, typically emerging in fall/winter and remitting in spring/summer. It's thought to relate to changes in circadian rhythms and reduced sunlight exposure.
Factors Contributing to Mood Disorders
Biological Factors
Genetics plays a significant role. First-degree relatives of individuals with MDD have a 2-4 times higher risk of developing the disorder compared to the general population. Twin studies show concordance rates for bipolar disorder of 40-70% in monozygotic (identical) twins versus only 5-10% in dizygotic (fraternal) twins, pointing to a strong heritable component.
Neurotransmitter imbalances involving serotonin, norepinephrine, and dopamine are implicated in mood disorders. The monoamine hypothesis proposes that depression results from a deficiency of these monoamine neurotransmitters, while mania may involve an excess. This hypothesis is supported by the mechanism of common antidepressants:
- SSRIs (selective serotonin reuptake inhibitors) block serotonin reuptake, increasing its availability in the synaptic cleft
- SNRIs (serotonin-norepinephrine reuptake inhibitors) block reuptake of both serotonin and norepinephrine
That said, the monoamine hypothesis is an oversimplification. These medications take weeks to produce clinical effects even though they change neurotransmitter levels within hours, suggesting more complex mechanisms are involved.
Brain structure and function differences have also been observed. Neuroimaging studies show decreased gray matter volume and reduced activity in the prefrontal cortex (involved in emotion regulation and cognitive control) in people with depression. The hippocampus, critical for learning and memory, tends to be smaller in individuals with a history of depression, possibly due to chronic stress impairing neurogenesis.
Psychological and Social Factors
Negative cognitive biases can contribute to the development and maintenance of depression. Beck's cognitive theory proposes that negative schemas (core beliefs about oneself, the world, and the future) generate automatic negative thoughts and cognitive distortions that perpetuate depressed mood. For example, someone might interpret a friend not texting back as proof that nobody cares about them.
Learned helplessness, a concept developed by Martin Seligman, describes what happens when individuals are exposed to uncontrollable stressors and come to believe their actions are futile. This sense of helplessness can generalize to new situations and increase vulnerability to depression.
Maladaptive coping strategies also play a role:
- Rumination (repetitively focusing on the causes and consequences of distress) predicts the onset, severity, and duration of depressive episodes because it interferes with problem-solving and keeps negative thought patterns active
- Avoidance (withdrawing from challenging situations or emotions) provides short-term relief but reinforces feelings of inadequacy over time
Stressful life events such as losing a loved one, relationship breakups, financial difficulties, or chronic health problems can trigger or worsen mood disorders in vulnerable individuals. The impact depends on the nature, severity, and duration of the stressor, as well as the person's coping resources and social support.
Childhood trauma, including physical, sexual, or emotional abuse, neglect, or exposure to domestic violence, is strongly associated with increased risk of mood disorders later in life. Adverse childhood experiences can produce lasting changes in brain regions involved in stress response and emotion regulation.
Social isolation and lack of support contribute to depression as well. Social support buffers against stress by providing emotional comfort, practical help, and a sense of belonging. Without it, feelings of hopelessness and worthlessness can intensify.
Socioeconomic disadvantage, including poverty, unemployment, and low educational attainment, is linked to higher rates of mood disorders. Financial hardship creates chronic stress, and limited access to healthcare and social services in disadvantaged communities can make it harder to get treatment.
Diathesis-Stress Model
The diathesis-stress model explains how mood disorders develop through the interaction of vulnerability and environment. A person carries a diathesis (predisposition) that may come from genetic factors, personality traits, or early life experiences. When that person encounters significant stress, it activates the underlying vulnerability, triggering the onset or recurrence of mood symptoms. Neither the predisposition nor the stress alone is typically sufficient to cause the disorder; it's the combination that matters.
Subtypes of Depression and Bipolar Disorder
Major Depressive Disorder Subtypes
Melancholic depression involves severe symptoms: psychomotor retardation (slowed movements and speech), early morning awakening, profound anhedonia, significant weight loss, and excessive guilt. Mood does not improve even when good things happen. Because of its stronger biological component, this subtype often responds well to antidepressant medication.
Atypical depression is in many ways the opposite pattern. Mood can improve temporarily in response to positive events. Other features include increased appetite or weight gain, hypersomnia, leaden paralysis, and a long-standing pattern of sensitivity to interpersonal rejection. It's associated with higher rates of comorbid anxiety and may respond better to MAOIs (monoamine oxidase inhibitors) than to other antidepressants.
Seasonal affective disorder (SAD) follows a predictable seasonal pattern, with symptoms typically appearing in fall/winter and lifting in spring/summer. It's linked to disrupted circadian rhythms and reduced sunlight. Treatment options include light therapy, antidepressant medication, and psychotherapy.
Bipolar Disorder Subtypes and Specifiers
Bipolar I disorder requires at least one manic episode severe enough to cause significant impairment in social or occupational functioning, and it may require hospitalization. Some individuals experience mixed features, where manic and depressive symptoms occur simultaneously.
Bipolar II disorder involves at least one hypomanic episode and one major depressive episode, with no full manic episodes. Hypomanic episodes are less severe and don't cause major functional impairment, though they can still be disruptive. People with bipolar II often spend more time in depressive episodes than hypomanic ones.
Cyclothymic disorder is a milder but chronic form, involving fluctuations between hypomanic and depressive symptoms over at least two years, with no symptom-free period lasting longer than two months. Though less severe than bipolar I or II, it still causes real distress and functional impairment.
Rapid cycling is a specifier applied to bipolar I or II when a person experiences four or more mood episodes within 12 months. It's associated with a more severe illness course, greater functional impairment, and higher suicide risk. Women are more likely to experience rapid cycling, and it may be linked to factors like hypothyroidism, antidepressant use, or substance abuse.
Treatment Options for Mood Disorders
Psychotherapy
Cognitive-behavioral therapy (CBT) targets the negative thought patterns and behaviors that maintain mood symptoms. It involves two key components:
- Cognitive restructuring: Identifying and challenging distorted thoughts like all-or-nothing thinking, overgeneralization, and catastrophizing
- Behavioral activation: Gradually re-engaging in pleasurable and meaningful activities to counteract the withdrawal and inactivity that come with depression
Interpersonal therapy (IPT) is a time-limited approach focused on improving relationships and addressing current life stressors. It helps individuals work through problematic patterns such as role disputes, role transitions, and interpersonal deficits. By building communication skills and social support, IPT aims to reduce depressive symptoms.
Other evidence-based options include dialectical behavior therapy (DBT), which emphasizes mindfulness, emotion regulation, and distress tolerance, and family-focused therapy (FFT), which educates family members about the disorder and improves communication within the family system.
Pharmacotherapy
Antidepressants are commonly used for depressive symptoms in both MDD and bipolar disorder:
- SSRIs (e.g., fluoxetine, sertraline, paroxetine) block serotonin reuptake, increasing serotonin availability. They're typically first-line due to a relatively favorable side effect profile.
- SNRIs (e.g., venlafaxine, duloxetine) block reuptake of both serotonin and norepinephrine, which may help with fatigue and concentration difficulties.
- TCAs (e.g., amitriptyline, imipramine) are older antidepressants that also block serotonin and norepinephrine reuptake but carry more significant side effects (anticholinergic and antihistaminic effects), so they're used less often today.
Mood stabilizers are the primary treatment for bipolar disorder:
- Lithium is a first-line treatment for bipolar I, with proven efficacy in reducing manic and depressive relapses and decreasing suicidal behavior
- Valproic acid (divalproex) is an anticonvulsant particularly effective for acute manic episodes and relapse prevention
- Lamotrigine is an anticonvulsant shown to be effective at preventing depressive episodes in bipolar disorder, though it's less effective for preventing mania
Atypical antipsychotics (e.g., quetiapine, olanzapine, risperidone) are sometimes used as adjunctive treatments, especially for treatment-resistant depression or bipolar disorder with psychotic features. They modulate dopamine and serotonin signaling but can cause significant side effects including weight gain, metabolic disturbances, and extrapyramidal symptoms (movement disorders).
Other Treatment Options
Electroconvulsive therapy (ECT) is highly effective for severe, treatment-resistant depression and bipolar disorder, particularly when suicide risk is high or rapid relief is needed. It involves inducing a brief, controlled seizure under general anesthesia. Modern techniques (unilateral electrode placement, brief pulse stimulation) have significantly reduced the memory loss and confusion historically associated with the procedure.
Transcranial magnetic stimulation (TMS) is a non-invasive technique that uses magnetic fields to stimulate the dorsolateral prefrontal cortex, a region involved in mood regulation. It's FDA-approved for treatment-resistant depression and has fewer side effects than medication or ECT. However, it may be less effective for severe or psychotic depression, and optimal treatment parameters are still being studied.
Light therapy (phototherapy) is a first-line treatment for SAD. It involves sitting in front of a light box emitting 10,000 lux of cool-white fluorescent light for 30-60 minutes per day, typically in the morning. It works by resynchronizing circadian rhythms and is thought to increase serotonin production.